Back when Kevetrin was just starting P1 clinical trials and prior to the Polymedix acquisition, a clinical trial junkie I became friends with at Dana-Farber told me that the more important the trial the more imperative it was that NO information whatsoever be leaked. She said the quieter the better and the more it spoke about the progress of the trial.

I have always remembered that knowledge being passed to me and feel that this trial is a prime example of it being true.

The unalterable quiet period IMO shows how Leo, and IPIX, have matured over the years and now know how to keep a lid on things. This will stand us shareholders in great shape over the next critical couple of years IMO.